Hisamitsu Pharmaceutical Co., Inc.
Notice Regarding the Results of the Tender Offer by Taiyo Kosan Co., Ltd. for Our Shares and the Change in Parent Company, Major Shareholder, Principal Shareholder and Major Shareholders
As a result of the tender offer concluded on February 19, 2026, Taiyo Kosan Co., Ltd. acquired 41,803,599 shares of Hisamitsu Pharmaceutical Co., Inc. (61.81% voting rights), and is expected to become the parent company and principal shareholder.
Key Figures
- Number of shares tendered: 41,803,599 shares (above the lower limit of 41,119,400 shares planned for acquisition)
- Voting rights ownership after acquisition: 61.81% (2.51% before acquisition)
- Tender price (per common share): ¥6,082
AI要約
Overview of Tender Offer Results
The tender offer by Taiyo Kosan Co., Ltd. for the common shares and stock acquisition rights of Hisamitsu Pharmaceutical Co., Inc. ended on February 19, 2026. The number of shares tendered was 41,803,599, exceeding the lower limit of 41,119,400 shares planned for acquisition, resulting in the tender offer being successful. Consequently, as of February 27, 2026, Taiyo Kosan is expected to change status to parent company and principal shareholder with a voting rights ratio of 61.81%. The tender price is ¥6,082 per common share, and the acquisition will be made in cash.
Future Outlook and Changes in Shareholder Composition
Following the successful tender offer, Taiyo Kosan plans significant changes to Hisamitsu Pharmaceutical’s shareholder structure with a view toward privatization. An extraordinary shareholders' meeting, including agenda items for share consolidation and amendments to the articles of incorporation, is scheduled for mid-April 2026. This is expected to lead to delisting from the stock exchange. Specific procedures and timing will be promptly announced after consultation with the offeror.
